Foresee Pharmaceuticals (Taiwan) Performance
| 6576 Stock | TWD 83.40 0.10 0.12% |
Foresee Pharmaceuticals has a performance score of 11 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.0976, which means not very significant fluctuations relative to the market. As returns on the market increase, Foresee Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Foresee Pharmaceuticals is expected to be smaller as well. Foresee Pharmaceuticals right now shows a risk of 0.85%. Please confirm Foresee Pharmaceuticals total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to decide if Foresee Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Foresee Pharmaceuticals Co are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Foresee Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 1.1 B | |
| Total Cashflows From Investing Activities | 17.6 M |
Foresee |
Foresee Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7,780 in Foresee Pharmaceuticals Co on December 26, 2024 and sell it today you would earn a total of 560.00 from holding Foresee Pharmaceuticals Co or generate 7.2% return on investment over 90 days. Foresee Pharmaceuticals Co is generating 0.1277% of daily returns and assumes 0.8451% volatility on return distribution over the 90 days horizon. Simply put, 7% of stocks are less volatile than Foresee, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Foresee Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Foresee Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Foresee Pharmaceuticals Co, and traders can use it to determine the average amount a Foresee Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.151
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | 6576 | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 0.85 actual daily | 7 93% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Foresee Pharmaceuticals is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Foresee Pharmaceuticals by adding it to a well-diversified portfolio.
Foresee Pharmaceuticals Fundamentals Growth
Foresee Stock prices reflect investors' perceptions of the future prospects and financial health of Foresee Pharmaceuticals, and Foresee Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Foresee Stock performance.
| Return On Equity | -0.35 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | (1.57) % | |||
| Operating Margin | (1.57) % | |||
| Current Valuation | 10.39 B | |||
| Shares Outstanding | 118.12 M | |||
| Price To Book | 10.24 X | |||
| Price To Sales | 39.29 X | |||
| Revenue | 226.03 M | |||
| EBITDA | (475.83 M) | |||
| Cash And Equivalents | 1.34 B | |||
| Cash Per Share | 11.47 X | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 9.36 X | |||
| Cash Flow From Operations | (213.33 M) | |||
| Earnings Per Share | (4.53) X | |||
| Total Asset | 1.64 B | |||
About Foresee Pharmaceuticals Performance
Evaluating Foresee Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Foresee Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Foresee Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Foresee Pharmaceuticals Co., Ltd., clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in Taiwan and Europe. Foresee Pharmaceuticals Co., Ltd. was founded in 2013 and is headquartered in Taipei, Taiwan. FORESEE PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about Foresee Pharmaceuticals performance evaluation
Checking the ongoing alerts about Foresee Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Foresee Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 226.03 M. Net Loss for the year was (569.27 M) with profit before overhead, payroll, taxes, and interest of 175.08 M. | |
| Foresee Pharmaceuticals Co has accumulated about 1.34 B in cash with (213.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.47. | |
| Roughly 35.0% of the company shares are owned by insiders or employees |
- Analyzing Foresee Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Foresee Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Foresee Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Foresee Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Foresee Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Foresee Pharmaceuticals' stock. These opinions can provide insight into Foresee Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Foresee Stock Analysis
When running Foresee Pharmaceuticals' price analysis, check to measure Foresee Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foresee Pharmaceuticals is operating at the current time. Most of Foresee Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Foresee Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foresee Pharmaceuticals' price. Additionally, you may evaluate how the addition of Foresee Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.